Acorah Software Products - Accounts Production 19.2.450 true true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 06863318 G J Boyle J E Keenlyside iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 06863318 2024-12-31 06863318 2025-12-31 06863318 2025-01-01 2025-12-31 06863318 frs-core:CurrentFinancialInstruments 2025-12-31 06863318 frs-core:Non-currentFinancialInstruments 2025-12-31 06863318 frs-core:ShareCapital 2025-12-31 06863318 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 06863318 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06863318 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 06863318 frs-bus:SmallEntities 2025-01-01 2025-12-31 06863318 frs-bus:EntityNoLongerTradingButTradedInPast 2025-01-01 2025-12-31 06863318 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06863318 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 06863318 frs-bus:Director1 2025-01-01 2025-12-31 06863318 frs-bus:Director2 2025-01-01 2025-12-31 06863318 frs-countries:EnglandWales 2025-01-01 2025-12-31 06863318 2023-12-31 06863318 2024-12-31 06863318 2024-01-01 2024-12-31 06863318 frs-core:CurrentFinancialInstruments 2024-12-31 06863318 frs-core:Non-currentFinancialInstruments 2024-12-31 06863318 frs-core:ShareCapital 2024-12-31 06863318 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31
Registered number: 06863318
Lynch Healthcare Limited
Unaudited Financial Statements
For The Year Ended 31 December 2025
Lynch Healthcare Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1
Notes to the Financial Statements | 2—3

Page 1
Lynch Healthcare Limited
Balance Sheet
As At 31 December 2025
Balance Sheet
Registered number: 06863318

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
CURRENT ASSETS
Stocks | 4 | 53,947 |  | 53,947 |
|  | 53,947 |  | 53,947 |
Creditors: Amounts Falling Due Within One Year | 5 | (34,838 ) |  | (34,838 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 19,109 |  | 19,109
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 19,109 |  | 19,109
Creditors: Amounts Falling Due After More Than One Year | 6 |  | (155,104 ) |  | (155,104 )
NET LIABILITIES |  |  | (135,995 ) |  | (135,995 )
CAPITAL AND RESERVES
Called up share capital | 7 |  | 100 |  | 100
Profit and Loss Account |  |  | (136,095 ) |  | (136,095 )
SHAREHOLDERS' FUNDS |  |  | (135,995) |  | (135,995)

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

J E Keenlyside Director
03/06/2026

The notes on pages 2 to 3 form part of these financial statements.
Page 1
Page 2
Lynch Healthcare Limited
Notes to the Financial Statements
For The Year Ended 31 December 2025
Notes to the Financial Statements
1. General Information
Lynch Healthcare Limited is a private company limited by shares, and incorporated in England and Wales. Its registered company number is 06863318, and its registered address is Unit 8 Withey Court, Western Industrial Estate, Caerphilly, Mid Glamorgan, United Kingdom, CF83 1BF.
The financial statements are prepared in Sterling, which is the functional currency of the Company. Monetary amounts in these financial statements are rounded to the nearest £1.
The principal activity of the company is that of a dormant company.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101, “Reduced Disclosure Framework” and the Companies Act 2006.
The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company’s accounting policies (see note 3).
2.2. Stocks and Work in Progress
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in. first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks ate impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Stocks

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Stock | 53,947 |  | 53,947

5. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Accruals and deferred income | 34,838 |  | 34,838

6. Creditors: Amounts Falling Due After More Than One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Bank loans | 155,104 |  | 155,104

7. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

Page 2
Page 3
Lynch Healthcare Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025
8. Post Balance Sheet Events
On 30th January 2026, Rhône, a global private equity firm, completed the acquisitions of Invacare Holdings SARL (Invacare Europe and APAC) and its subsidiaries and DHG Holdco SARL and its subsidiaries, combining the businesses and associated brands to create DHCare, with the aim to be one of the international leaders in designing, manufacturing and distributing medical devices in the mobility and post-acute care sectors. Archimed have also retained a minority share in the newly combined business.
Page 3